Orange Book product · Generic (ANDA)
FLUTICASONE PROPIONATE
FLUTICASONE PROPIONATE
At a glance
Mar 03, 2026
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Mar 03, 2026
4 mo ago
Today
Exclusivity ends · CGT
FDA marketing exclusivity
Sep 20, 2026
in 3 mo
Pharmaceutical detail
Active ingredient
FLUTICASONE PROPIONATE
Strength
0.044MG/INH
Dosage form
AEROSOL, METERED
Route
INHALATION
TE code
AB
Application
ANDA 219602
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of FLUTICASONE PROPIONATE
- 2022ARMONAIR DIGIHALERBrand (NDA)
NDA 208798 · TEVA PHARM
- 2017XHANCEBrand (NDA)
NDA 209022 · PARATEK PHARMS
- 2014FLONASE ALLERGY RELIEFBrand (NDA)
NDA 205434 · HALEON US HOLDINGS
- 2005CUTIVATEBrand (NDA)
NDA 021152 · FOUGERA PHARMS
- 2004FLOVENT HFABrand (NDA)
NDA 021433 · GLAXO GRP LTD
- 2000FLOVENT DISKUS 100Brand (NDA)
NDA 020833 · GLAXO GRP LTD
- 1997FLOVENTBrand (NDA)
NDA 020549 · GLAXOSMITHKLINE
- 1996FLOVENTBrand (NDA)
NDA 020548 · GLAXOSMITHKLINE
- 1994FLONASEBrand (NDA)
NDA 020121 · HALEON US HOLDINGS
- 1990CUTIVATEBrand (NDA)
NDA 019958 · FOUGERA PHARMS
- 1990CUTIVATEBrand (NDA)
NDA 019957 · FOUGERA PHARMS
- 2026FLUTICASONE PROPIONATEGeneric (ANDA)
ANDA 218742 · GLENMARK SPECLT
Marketing exclusivity (1)
- CGTFDA marketing exclusivity
Sep 20, 2026
in 3 mo
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
